Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05477953 · ClinicalTrials.gov registry record
An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health
A clinical trial, sponsored by Bayer.
- Not yet
- Registry status
- 50
- Enrollment target
NCT05477953 is a clinical trial that has not yet begun recruiting, run by Bayer. The registered enrollment target is 50 participants.
The verdict
NCT05477953 has not yet begun recruiting, sponsored by Bayer.
- NOT YET RECRUITING
- Registry status
- 50 participants
- Enrollment target
Study Summary
This is an observational study in which data from women with Chagas disease who will take or have already taken nifurtimox during pregnancy and the impact on their babies are studied. Chagas disease is an inflammatory, infectious disease caused by the parasite Trypanosoma cruzi. This parasite is mainly spread by insects called triatomine bug. If Chagas disease is left untreated, it can later cause e.g. serious heart and digestive problems. Nifurtimox has been used for more than 50 years to treat Chagas disease in children and adults. It is not recommended to be used during pregnancy as data from animal studies indicate that it may harm the baby. Currently, there are not enough data to know if this is also the case in humans. In this study, researchers want to collect data on the safety of nifurtimox use in pregnant women. To do this, researchers will collect the following information: * Birth defects (abnormal and problematic structures or functions, a child is born with) * Pregnancy outcomes (like live birth, preterm birth, still birth/death of the unborn baby, miscarriage, or abortion) * Certain health problems of the child up to 12 months of age * Certain health problems of the women experienced during pregnancy The data will be collected from different sources including telephone calls with the women or their doctor, CRFs (case reprt forms) or from medical records The researchers will compare the proportion of children with birth defects, pregnancy outcomes or certain health problems of the child or the women during pregnancy with available data on these outcomes in the general population. The study will run for approximately 10 years.
Interventions
- DRUG Nifurtimox (BAYA2502)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-12-31 |
| Est. Completion | 2032-01-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05477953
The ClinicalTrials.gov registry entry for NCT05477953 describes a study currently listed as not yet recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nifurtimox (BAYA2502) is the first listed.
NCT05477953 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05477953 about?
NCT05477953 is a clinical study titled "An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health". This is an observational study in which data from women with Chagas disease who will take or have already taken nifurtimox during pregnancy and the impact on their babies are studied. Chagas disease is an inflammatory, infectious disease caused by the parasite Trypanosoma cruzi. This parasite is ma...
What is the current status of trial NCT05477953?
This trial is currently not yet recruiting. The enrollment target is 50 participants. The study started on 2026-12-31. Estimated completion is 2032-01-31.
What interventions are being tested in trial NCT05477953?
The interventions under investigation include: Nifurtimox (BAYA2502) (DRUG).
Who is sponsoring clinical trial NCT05477953?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.